on Neurocentria Inc.
New Research Highlights Magnesium's Role in Brain Synapses and Cognition
Neurocentria Inc., a late-stage biotechnology company, has unveiled new research emphasizing the crucial role of magnesium in brain function and cognitive health. The study, published in Nature Communications, establishes how magnesium levels influence synaptic connections between neurons.
The research, a collaboration between Neurocentria and Tsinghua University, reveals that high intracellular magnesium levels lead to numerous weak synaptic configurations, beneficial for learning and encoding new information. Conversely, low magnesium levels result in fewer but stronger synaptic connections, ideal for memory storage. This finding is particularly relevant for aging brains, where synapses tend to be organized in a low-magnesium configuration, hindering the formation of new memories.
Dr. Guosong Liu, co-founder and CEO of Neurocentria, stated that these findings could make intracellular magnesium a pivotal drug target for treating neurological disorders. With half the global population experiencing magnesium deficiency, maintaining adequate levels could mitigate age-related cognitive decline and potentially treat conditions impacting cognitive function.
Neurocentria is advancing NRCT-101SR, aimed at enhancing magnesium delivery to brain synapses. The compound has shown promise in clinical trials, improving learning, memory, and emotional regulation in older adults with mild cognitive impairment and other neurological conditions.
The company is currently conducting late-stage trials to further examine the benefits of brain magnesium elevation for treating ADHD, depression, and other disorders.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Neurocentria Inc. news